ACTA1 and melanoma: The use of CM from Bcl-2 overexpressing melanoma cells treated with the specific YAP inhibitor Verteporfin, reduced in vitro fibroblasts migration, and both α-SMA protein level and ERK phosphorylation, indicating the involvement of YAP in fibroblast activation by cancer-specific Bcl-2.